tiprankstipranks
Eckert & Ziegler Strahlen- und Medizintechnik AG (DE:EUZ)
XETRA:EUZ
Want to see DE:EUZ full AI Analyst Report?

Eckert & Ziegler Strahlen und Medizintechnik (EUZ) Price & Analysis

29 Followers

EUZ Stock Chart & Stats

€15.59
-€1.00(-2.03%)
At close: 4:00 PM EST
€15.59
-€1.00(-2.03%)

Bulls Say, Bears Say

Bulls Say
Strong Margins And ProfitabilitySustained high gross, operating and EBITDA margins indicate differentiated products and scale in radiopharmaceuticals. Such margin breadth supports durable earnings generation, reinvestment capacity and resilience to moderate volume swings over the next 2–6 months.
Conservative Balance Sheet And High ROELow leverage and strong returns on equity provide financial flexibility for capex, targeted investments or partnerships without stressing solvency. This capital conservatism reduces refinancing risk and supports durable strategic optionality in a regulated industry.
Structural Demand And Supply AdvantagesThe business supplies critical radioisotopes and services where reliability and compliance matter. Regulatory barriers and entrenched customer supply relationships create durable competitive advantages, supporting stable revenue streams and pricing power over medium term.
Bears Say
Weak Free Cash Flow ConversionFree cash flow covering only half of reported net income and showing a downtrend raises concern about earnings quality and internal funding capacity. Persistent weak conversion limits dividend, buyback or investment flexibility and increases reliance on working-capital or financing actions.
Profitability VolatilityA history of materially higher past net margins followed by normalization suggests sensitivity to product mix, pricing or cost swings. Such margin volatility complicates forward earnings predictability and planning for sustained reinvestment or shareholder returns.
Balance-sheet VariabilityShifts in total assets year-to-year indicate non-steady investment or working-capital patterns. This variability can translate into timing risk for cash flow and capital deployment, requiring closer monitoring of capex, inventory and receivables management.

EUZ FAQ

What was Eckert & Ziegler Strahlen- und Medizintechnik AG’s price range in the past 12 months?
Eckert & Ziegler Strahlen- und Medizintechnik AG lowest stock price was €13.30 and its highest was €23.25 in the past 12 months.
    What is Eckert & Ziegler Strahlen- und Medizintechnik AG’s market cap?
    Eckert & Ziegler Strahlen- und Medizintechnik AG’s market cap is €965.52M.
      When is Eckert & Ziegler Strahlen- und Medizintechnik AG’s upcoming earnings report date?
      Eckert & Ziegler Strahlen- und Medizintechnik AG’s upcoming earnings report date is Aug 13, 2026 which is in 60 days.
        How were Eckert & Ziegler Strahlen- und Medizintechnik AG’s earnings last quarter?
        Eckert & Ziegler Strahlen- und Medizintechnik AG released its earnings results on May 12, 2026. The company reported €0.166 earnings per share for the quarter, beating the consensus estimate of N/A by €0.166.
          Is Eckert & Ziegler Strahlen- und Medizintechnik AG overvalued?
          According to Wall Street analysts Eckert & Ziegler Strahlen- und Medizintechnik AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Eckert & Ziegler Strahlen- und Medizintechnik AG pay dividends?
            Eckert & Ziegler Strahlen- und Medizintechnik AG pays a Annually dividend of €0.22 which represents an annual dividend yield of 1.11%. See more information on Eckert & Ziegler Strahlen- und Medizintechnik AG dividends here
              What is Eckert & Ziegler Strahlen- und Medizintechnik AG’s EPS estimate?
              Eckert & Ziegler Strahlen- und Medizintechnik AG’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Eckert & Ziegler Strahlen- und Medizintechnik AG have?
              Eckert & Ziegler Strahlen- und Medizintechnik AG has 63,515,797 shares outstanding.
                What happened to Eckert & Ziegler Strahlen- und Medizintechnik AG’s price movement after its last earnings report?
                Eckert & Ziegler Strahlen- und Medizintechnik AG reported an EPS of €0.166 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.176%.
                  Which hedge fund is a major shareholder of Eckert & Ziegler Strahlen- und Medizintechnik AG?
                  Currently, no hedge funds are holding shares in DE:EUZ
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Eckert & Ziegler Strahlen und Medizintechnik Stock Smart Score

                    Company Description

                    Eckert & Ziegler Strahlen- und Medizintechnik AG

                    Eckert & Ziegler Strahlen- und Medizintechnik AG, along with its various subsidiaries, is a global specialist in the production and delivery of sophisticated isotope technology components. These components are utilized across a broad spectrum of medical, scientific, and industrial applications worldwide. The company operates through two primary divisions: Medical and Isotope Products. The Medical segment focuses on therapeutic radioactive solutions. This includes furnishing tiny radioactive implants, often called 'seeds,' for prostate cancer therapy, as well as developing ocular applicators containing ruthenium-106 or iodine-125 to treat uveal melanoma. Additionally, this division supplies radiopharmaceutical compounds, specialized laboratory equipment, shielded hot cells, and related services for radiopharmaceuticals, in addition to their dedicated eye applicators and prostate implants. The Isotope Products segment is responsible for manufacturing and distributing radiation sources essential for a range of technical processes. These encompass medical imaging, precise measurement systems, material characterization, quality assurance protocols, and environmental surveillance. Furthermore, this division provides calibration sources vital for medical diagnostic imaging systems, alongside products designed for national security purposes and radiometric level sensing. Founded in 1992, the company maintains its corporate headquarters in Berlin, Germany.

                    Eckert & Ziegler Strahlen und Medizintechnik (EUZ) Earnings & Revenues

                    EUZ Stock 12 Month Forecast

                    Average Price Target

                    €20.30
                    ▲(30.21% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"€14","23":"€23","16.25":"€16.25","18.5":"€18.5","20.75":"€20.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€20.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€20.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€20.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,16.25,18.5,20.75,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.19,16.506153846153847,16.822307692307692,17.138461538461538,17.454615384615387,17.770769230769233,18.086923076923078,18.403076923076924,18.71923076923077,19.035384615384615,19.35153846153846,19.66769230769231,19.983846153846155,{"y":20.3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.19,16.506153846153847,16.822307692307692,17.138461538461538,17.454615384615387,17.770769230769233,18.086923076923078,18.403076923076924,18.71923076923077,19.035384615384615,19.35153846153846,19.66769230769231,19.983846153846155,{"y":20.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.19,16.506153846153847,16.822307692307692,17.138461538461538,17.454615384615387,17.770769230769233,18.086923076923078,18.403076923076924,18.71923076923077,19.035384615384615,19.35153846153846,19.66769230769231,19.983846153846155,{"y":20.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.574,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.099,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.599,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.93,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.92,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.26,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.06,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.11,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.19,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Gerresheimer
                    MeVis Medical Solutions
                    STRATEC Biomedical
                    Siemens Healthineers AG
                    MagForce AG

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks